The biotech firm reports first full-quarter sales of its new therapy, up sharply from $3.4 million in Q4.
Precigen reported $21.6 million in net product revenue for PAPZIMEOS in Q1 2026, its first full quarter of commercial availability. The figure marks a significant increase from $3.4 million in the prior quarter, reflecting early scaling success for the therapy.
Management highlighted robust revenue growth during the earnings call, citing accelerating demand. The company now expects to reach cash flow breakeven by the end of 2026 as the launch progresses.
No immediate market reaction was disclosed in the call summary.